©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):36-39, 2026. ISSN: 2550-794X

https://doi.org/10.59298/IDOSRJSR/2026/11.2.3639 IDOSRJSR11106

Mesenchymal Stem Cell Transplantation as Regenerative Therapy for Type 1 Diabetes: A Systematic Review

Mukisa Ian Mugaiga

Department of Pharmacology Kampala International University Uganda
Email:mugaiga.mukisa@studwc.kiu.ac.ug

ABSTRACT

Type 1 diabetes is a chronic autoimmune disorder characterized by immune-mediated destruction of pancreatic beta cells, resulting in lifelong dependence on exogenous insulin and risk of acute and chronic metabolic complications. Despite advances in insulin formulations and glucose monitoring technologies, current therapies have not restored endogenous insulin secretion nor corrected the underlying immune dysregulation. Mesenchymal stem cell transplantation emerged as a potential regenerative and immunomodulatory strategy aimed at preserving or restoring beta cell mass. The purpose of this systematic review was to critically evaluate preclinical and clinical evidence supporting the therapeutic role of mesenchymal stem cells in Type 1 Diabetes. A structured systematic search of major biomedical databases was conducted, applying predefined inclusion and exclusion criteria and qualitative synthesis of eligible studies. Available evidence indicated that mesenchymal stem cells exert beneficial effects through immunomodulation, anti-inflammatory signaling, enhancement of islet survival, and promotion of endogenous repair mechanisms, with several early-phase clinical trials demonstrating improvements in C-peptide levels, reduced insulin requirements, and favorable safety profiles. However, heterogeneity in cell sources, dosing protocols, and study design limited definitive conclusions regarding long-term efficacy. Mesenchymal stem cell transplantation represented a promising but still investigational approach for Type 1 Diabetes, warranting rigorous large-scale trials and standardized therapeutic protocols.

Keywords: Type 1 Diabetes, Mesenchymal stem cells, Beta cell regeneration, Immunomodulation, Regenerative medicine.

INTRODUCTION

Type 1 diabetes is an autoimmune endocrine disorder characterized by selective destruction of insulin-producing beta cells within the pancreatic islets of Langerhans [1, 2]. The disease results from complex interactions between genetic susceptibility, environmental triggers, and dysregulated immune responses, culminating in progressive beta cell loss and absolute insulin deficiency [3]. Although exogenous insulin therapy remains the cornerstone of management, it does not replicate physiological glucose-responsive insulin secretion and fails to address the underlying immune pathology. Patients remain vulnerable to hypoglycemia, glycemic variability, and long-term microvascular and macrovascular complications [4].

The fundamental therapeutic challenge in Type 1 Diabetes lies in restoring endogenous beta cell mass while simultaneously re-establishing immune tolerance [5, 6]. Conventional immunosuppressive strategies have demonstrated limited durability and carry potential adverse effects. Islet transplantation offers proof of concept for cellular replacement but is constrained by donor scarcity, immune rejection, and the requirement for chronic immunosuppression.

Mesenchymal stem cells have attracted considerable attention as candidates for regenerative therapy due to their multipotent differentiation capacity, paracrine signaling properties, and profound immunomodulatory effects [7]. Derived from bone marrow, adipose tissue, umbilical cord, and other sources, these cells can influence inflammatory pathways, promote tissue repair, and potentially support beta cell survival or regeneration. This review examines the pathophysiological rationale for regenerative intervention, the biological characteristics and mechanisms of

mesenchymal stem cells, the methodology employed in evaluating current evidence, the outcomes of preclinical and clinical studies, and the translational challenges facing clinical implementation. The purpose of this study is to provide a comprehensive and critical synthesis of existing data to determine the therapeutic promise and limitations of mesenchymal stem cell transplantation in Type 1 Diabetes.

Pathophysiology of Type 1 Diabetes and Rationale for Regenerative Therapy

Type 1 Diabetes is mediated by autoreactive T lymphocytes that target pancreatic beta cell antigens such as insulin, glutamic acid decarboxylase, and islet antigen 2 [8, 9]. Genetic predisposition, particularly within human leukocyte antigen loci, confers susceptibility, while environmental factors may initiate immune activation. The inflammatory cascade involves infiltration of pancreatic islets by CD4 and CD8 T cells, macrophages, and dendritic cells, resulting in cytokine-mediated apoptosis of beta cells.

Proinflammatory mediators including interleukin 1 beta, tumor necrosis factor alpha, and interferon gamma activate intracellular stress pathways, induce nitric oxide production, and promote oxidative damage [10]. Progressive beta cell destruction culminates in insulin deficiency, hyperglycemia, and metabolic dysregulation. Even with intensive insulin therapy, residual endogenous secretion often declines over time.

The rationale for regenerative therapy is grounded in the recognition that preservation or restoration of functional beta cell mass could improve metabolic stability and reduce complications. Furthermore, modulation of the autoimmune response is essential to prevent recurrent destruction. An ideal regenerative strategy must therefore combine tissue repair with immune regulation. Mesenchymal stem cell transplantation is conceptually attractive because it offers dual capacity to modulate immune responses and promote endogenous repair processes [11]. Unlike conventional immunosuppressive agents, these cells may induce immune tolerance while supporting tissue regeneration. This integrated approach aligns closely with the complex pathobiology of Type 1 Diabetes.

Biological Characteristics and Therapeutic Mechanisms of Mesenchymal Stem Cells

Mesenchymal stem cells are multipotent stromal cells characterized by adherence to plastic in culture, expression of surface markers such as CD73, CD90, and CD105, and absence of hematopoietic markers [12]. They can be isolated from bone marrow, adipose tissue, umbilical cord tissue, and other mesenchymal compartments. Their therapeutic potential extends beyond differentiation into mesodermal lineages.

Mesenchymal stem cells secrete growth factors, cytokines, extracellular vesicles, and microRNAs that influence local cellular environments [13]. These secreted factors can reduce inflammation, inhibit apoptosis, and enhance angiogenesis within pancreatic tissue. In experimental models, mesenchymal stem cells have been shown to preserve residual beta cells and improve islet vascularization. Mesenchymal stem cells suppress proliferation of autoreactive T cells, promote expansion of regulatory T cells, and modulate dendritic cell maturation [14, 15]. They can shift cytokine profiles from proinflammatory to anti-inflammatory states, thereby attenuating autoimmune destruction.

Although direct differentiation into insulin-producing cells has been reported under specific culture conditions, the predominant therapeutic effects in vivo appear to derive from immunoregulatory and trophic mechanisms rather than true transdifferentiation. This distinction is essential for realistic expectations regarding clinical outcomes. The combined anti-inflammatory, cytoprotective, and pro-regenerative properties of mesenchymal stem cells provide a compelling biological rationale for their application in Type 1 Diabetes.

Clinical and Preclinical Evidence of Mesenchymal Stem Cell Transplantation in Type 1 Diabetes

Preclinical studies in non-obese diabetic mice and chemically induced diabetic models have demonstrated that mesenchymal stem cell administration can delay disease onset, reduce insulitis, and improve glycemic control [16]. Treated animals often exhibit increased circulating C-peptide levels and preservation of islet architecture. Mechanistic analyses reveal decreased proinflammatory cytokine expression and enhanced regulatory T cell populations [17].

In clinical settings, early phase trials have explored autologous and allogeneic mesenchymal stem cell transplantation in newly diagnosed and established Type 1 Diabetes patients [18]. Several studies report transient or sustained increases in C-peptide levels, reduced daily insulin requirements, and improved glycemic variability. Some participants achieved partial remission, characterized by improved metabolic control with lower exogenous insulin doses.

Safety profiles in these trials have generally been favorable, with mild infusion-related reactions and no consistent evidence of severe adverse events during short- to medium term follow up. However, variability in cell preparation methods, dosing regimens, and routes of administration complicates direct comparison across studies. Long-term durability of metabolic improvement remains uncertain. Some trials demonstrate waning effects over time, suggesting that repeated dosing or combination therapies may be necessary. Nonetheless, the cumulative evidence indicates that mesenchymal stem cell transplantation exerts measurable biological and clinical effects in Type 1 Diabetes [19].

Translational Challenges, Safety Considerations, and Future Directions

Despite encouraging findings, significant challenges must be addressed before routine clinical application can be realized. Standardization of cell isolation, expansion, and characterization protocols is essential to ensure reproducibility [20]. Variability in donor characteristics and tissue sources may influence therapeutic potency.

Optimal dosing strategies, timing of intervention, and route of administration require clarification. Early intervention soon after diagnosis may yield greater benefit by preserving residual beta cell mass, yet this hypothesis demands validation in controlled trials [21]. Long-term safety remains a paramount concern. Although mesenchymal stem cells are generally considered safe, theoretical risks include unwanted differentiation, ectopic tissue formation, and immune sensitization. Rigorous post-treatment surveillance is therefore necessary.

Regulatory frameworks governing cell-based therapies vary across jurisdictions, creating additional complexity. Economic considerations, scalability of manufacturing, and equitable access in diverse health systems must also be addressed. Future research should prioritize large randomized controlled trials, standardized outcome measures, and mechanistic studies elucidating immune modulation pathways. Integration with adjunctive therapies, including antigen-specific immunotherapy, may enhance durability of response.

CONCLUSION

Mesenchymal stem cell transplantation represents a biologically plausible and increasingly investigated regenerative strategy for Type 1 Diabetes. By combining immunomodulatory capacity with trophic support for pancreatic tissue, these cells address central elements of disease pathogenesis that are not corrected by exogenous insulin therapy alone. Preclinical studies consistently demonstrate preservation of beta cell mass and modulation of inflammatory responses, while early clinical trials suggest improvements in endogenous insulin secretion and metabolic control with acceptable short-term safety profiles. Nevertheless, heterogeneity in study design, limited sample sizes, and variable follow-up durations constrain definitive conclusions regarding long-term efficacy and durability. Critical gaps remain in understanding optimal cell source, dosing regimens, timing of intervention, and mechanisms underlying sustained immune tolerance. Standardized manufacturing protocols and rigorous regulatory oversight will be essential for safe translation into widespread clinical practice. Well-designed, adequately powered randomized controlled trials with long-term follow-up are strongly recommended to determine whether mesenchymal stem cell transplantation can evolve from experimental therapy to an established disease-modifying treatment for individuals with Type 1 Diabetes.

REFERENCES

1. Roep, B.O., Thomaidou, S., van Tienhoven, R., Zaldumbide, A.: Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 17, 150–161 (2021). https://doi.org/10.1038/s41574-020-00443-4
2. Ugwu, O.P.-C., Erisa, K., Obeagu., E.I., Alum, E.U., Michael B, O., Subbarayan, S., Sankarapandiyan, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR ES. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000
3. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
4. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
5. Rathod, S.: Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes. Diabetology. 3, 79–96 (2022). https://doi.org/10.3390/diabetology3010007
6. Carroll, K.R., Elfers, E.E., Stevens, J.J., McNally, J.P., Hildeman, D.A., Jordan, M.B., Katz, J.D.: Extending Remission and Reversing New-Onset Type 1 Diabetes by Targeted Ablation of Autoreactive T Cells. Diabetes. 67, 2319–2328 (2018). https://doi.org/10.2337/db18-0204
7. Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., Liu, X.: Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther. 11, 345 (2020). https://doi.org/10.1186/s13287-020-01855-9
8. Roep, B.O., Thomaidou, S., van Tienhoven, R., Zaldumbide, A.: Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 17, 150–161 (2021). https://doi.org/10.1038/s41574-020-00443-4
9. Mauvais, F.-X., van Endert, P.M.: Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians. Diabetes, Obesity and Metabolism. 27, 40–56 (2025). https://doi.org/10.1111/dom.16460

10. Vallée, A., Lecarpentier, Y.: Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis. Front. Immunol. 9, (2018). https://doi.org/10.3389/fimmu.2018.00745
11. Jiang, W., Xu, J.: Immune modulation by mesenchymal stem cells. Cell Proliferation. 53, e12712 (2020). https://doi.org/10.1111/cpr.12712
12. Santoro, A., Grimaldi, M., Marino, C., Napolitano, E., Buonocore, M., D'Ursi, A.M.: Cell Surface Markers of Mesenchymal Stem Cells: Current Knowledge and Advances in Characterization Technologies. Life. 16, (2025). https://doi.org/10.3390/life16010010
13. Ragni, E., Orfei, C.P., Luca, P.D., Colombini, A., Viganò, M., Girolamo, L. de: Secreted Factors and EV-miRNAs Orchestrate the Healing Capacity of Adipose Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis. International Journal of Molecular Sciences. 21, (2020). https://doi.org/10.3390/ijms21051582
14. Negi, N., Griffin, M.D.: Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Stem Cells. 38, 596–605 (2020). https://doi.org/10.1002/stem.3151
15. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
16. Klinker, M.W., Wei, C.-H.: Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. World J Stem Cells. 7, 556–567 (2015). https://doi.org/10.4252/wjsc.v7.i3.556
17. Polesso, F., Sarker, M., Anderson, A., Parker, D.C., Murray, S.E.: Constitutive expression of NF-κB inducing kinase in regulatory T cells impairs suppressive function and promotes instability and pro-inflammatory cytokine production. Sci Rep. 7, 14779 (2017). https://doi.org/10.1038/s41598-017-14965-x
18. Izadi, M., Sadr Hashemi Nejad, A., Moazenchi, M., Masoumi, S., Rabbani, A., Kompani, F., Hedayati Asl, A.A., Abbasi Kakroodi, F., Jaroughi, N., Mohseni Meybodi, M.A., Setoodeh, A., Abbasi, F., Hosseini, S.E., Moeini Nia, F., Salman Yazdi, R., Navabi, R., Hajizadeh-Saffar, E., Baharvand, H.: Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. Stem Cell Res Ther. 13, 264 (2022). https://doi.org/10.1186/s13287-022-02941-w
19. Madani, S., Amanzadi, M., Aghayan, H.R., Setudeh, A., Rezaei, N., Rouhifard, M., Larijani, B.: Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst Rev. 11, 82 (2022). https://doi.org/10.1186/s13643-022-01950-3
20. Palumbo, P., Lombardi, F., Siragusa, G., Cifone, M.G., Cinque, B., Giuliani, M.: Methods of Isolation, Characterization and Expansion of Human Adipose-Derived Stem Cells (ASCs): An Overview. International Journal of Molecular Sciences. 19, (2018). https://doi.org/10.3390/ijms19071897
21. McVean, J., Forlenza, G.P., Beck, et al.: Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 329, 980 (2023). https://doi.org/10.1001/jama.2023.2063

CITE AS: Mukisa Ian Mugaiga (2026). Mesenchymal Stem Cell Transplantation as Regenerative Therapy for Type 1 Diabetes: A Systematic Review. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):36-39. https://doi.org/10.59298/IDOSRJSR/2026/11.2.3639